SCHEMBL24252637

SCHEMBL24252637

Nc1ccnc2cc(-c3cc(B(O)O)ccc3OCCC3CCCO3)ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.36
IRAK4 Q9NWZ3 3/20 0.36
CTSD P07339 3/20 0.34
MAP4K4 O95819 2/20 0.33
TLR8 Q9NR97 1/20 0.33
PIK3CA P42336 1/20 0.32
EHMT2 Q96KQ7 1/20 0.32
EHMT1 Q9H9B1 1/20 0.32
EGLN1 Q9GZT9 1/20 0.32
PRKAB2 O43741 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA2 P54646 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAG3 Q9UGI9 1/20 0.31
PRKAG2 Q9UGJ0 1/20 0.31
PRKAB1 Q9Y478 1/20 0.31
GRM4 Q14833 1/20 0.31
TGFBR1 P36897 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26772601 0.93 IRAK4 (0.39) CNR2IRAK4CTSDMAP4K4TLR8
SCHEMBL24252633 0.88 CNR2 (0.36) CNR2CTSDMAP4K4PIK3CAPRKAB2
SCHEMBL26771261 0.81 CNR2 (0.35) CNR2IRAK4CTSDMAP4K4PIK3CA
SCHEMBL24252495 0.79 CNR2 (0.38) CNR2IRAK4CTSDPIK3CAGRM4
SCHEMBL24252635 0.76 DHFR (0.43) MAP4K4TLR8EHMT2EHMT1TGFBR1
Formic Acid SCHEMBL30467691 0.75 CNR2 (0.36) CNR2IRAK4CTSDMAP4K4PIK3CA
Formic Acid SCHEMBL25267074 0.75 CNR2 (0.36) CNR2IRAK4CTSDMAP4K4PIK3CA
SCHEMBL24252357 0.74 PDE10A (0.36) PIK3CA
SCHEMBL24252776 0.73 PIK3CA (0.34) PIK3CAPRKAB2PRKAG1PRKAA2PRKAA1
Formic Acid SCHEMBL25259305 0.72 DHFR (0.39) MAP4K4TLR8EHMT2EHMT1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CNR2 1499/4885IRAK4 577/4885CTSD 403/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 CNR2 1499/4885IRAK4 577/4885CTSD 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.